NYSE · STVN
Healthcare · Medical - Instruments & Supplies
$21.70
Up+$0.19 (+0.88%)
Updated Sep 23, 2026, 3:23 AM
SID Score
5.0/10
Composite research score
Smart Money
56/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
STVN closed at $21.70 after 20 trading sessions, down 4.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $21.42 | $21.91 | $21.0663 | $21.70 | 217.44K |
| Sep 21, 2026 | $21.91 | $22.17 | $21.185 | $21.51 | 475.48K |
| Sep 18, 2026 | $22.60 | $23.254 | $21.61 | $21.70 | 265.55K |
| Sep 17, 2026 | $22.66 | $23.18 | $22.53 | $22.67 | 507.12K |
| Sep 16, 2026 | $21.51 | $22.53 | $21.43 | $22.53 | 603.5K |
| Sep 15, 2026 | $21.15 | $21.87 | $20.63 | $21.54 | 295.15K |
| Sep 14, 2026 | $20.61 | $21.33 | $20.03 | $21.32 | 266.32K |
| Sep 11, 2026 | $20.96 | $21.35 | $20.71 | $20.90 | 885.74K |
| Sep 10, 2026 | $20.09 | $20.98 | $20.07 | $20.95 | 279.12K |
| Sep 9, 2026 | $20.25 | $20.78 | $20.00 | $20.24 | 221.24K |
| Sep 8, 2026 | $20.49 | $20.66 | $20.22 | $20.32 | 205.63K |
| Sep 4, 2026 | $20.26 | $20.60 | $19.74 | $20.51 | 212.89K |
| Sep 3, 2026 | $20.71 | $20.79 | $20.4011 | $20.54 | 168.96K |
| Sep 2, 2026 | $20.64 | $21.23 | $20.47 | $20.73 | 217.19K |
| Sep 1, 2026 | $21.24 | $21.35 | $20.63 | $20.71 | 253.86K |
| Aug 31, 2026 | $21.80 | $21.80 | $20.93 | $21.43 | 335.72K |
| Aug 28, 2026 | $22.23 | $22.26 | $20.86 | $21.03 | 344.07K |
| Aug 27, 2026 | $22.28 | $22.6399 | $22.06 | $22.30 | 306.26K |
| Aug 26, 2026 | $22.56 | $23.00 | $22.25 | $22.38 | 499.24K |
| Aug 25, 2026 | $22.24 | $23.08 | $22.00 | $22.70 | 204.6K |
The latest Smart Investors Daily articles mentioning STVN.
STVN research
Company profile and research snapshot.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Jun 16, 2026 | TD Cowen | Buy | — |
| Mar 6, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SeekingAlpha · Sep 15, 2026
Stevanato Group S.p.A. (STVN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:50 PM EDTCompany ParticipantsMarco Dal Lago -...
SeekingAlpha · Sep 11, 2026
Benzinga · Sep 9, 2026
UBS analyst Dan Leonard maintains Stevanato Group (NYSE:STVN) with a Neutral and lowers the price target from $28 to $23.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STVN.
